Cleveland State University

EngagedScholarship@CSU
Chemistry Faculty Publications

Chemistry Department

2003

A Phase I and Pharmacologic Study of Weekly Gemcitabine in
Combination with Infusional 5-fluorodeoxyuridine and Oral
Calcium Leucovorin
Jean L. Grem
National Cancer Institute-Navy Medical Oncology

Mary G. Quinn
National Cancer Institute-Navy Medical Oncology

Bruce Keith
National Cancer Institute-Navy Medical Oncology

Brian P. Monahan
National Naval Medical Center

J. Michael Hamilton

Follow this and additional works at: https://engagedscholarship.csuohio.edu/scichem_facpub
National Cancer Institute-Navy Medical Oncology
Part of the Chemistry Commons

How does access to this work benefit you? Let us know!
See next page for additional authors

Publisher's Statement

The final publication is available at Springer via http://dx.doi.org/10.1007/s00280-003-0698-5
Recommended Citation
Grem, Jean L.; Quinn, Mary G.; Keith, Bruce; Monahan, Brian P.; Hamilton, J. Michael; Xu, Yan; Harold,
Nancy; Nguyen, Dat; Takimoto, Chris H.; Rowedder, Anthony; Pang, Janet; Morrison, Geraldine; and Chen,
Alice, "A Phase I and Pharmacologic Study of Weekly Gemcitabine in Combination with Infusional
5-fluorodeoxyuridine and Oral Calcium Leucovorin" (2003). Chemistry Faculty Publications. 167.
https://engagedscholarship.csuohio.edu/scichem_facpub/167

This Article is brought to you for free and open access by the Chemistry Department at EngagedScholarship@CSU.
It has been accepted for inclusion in Chemistry Faculty Publications by an authorized administrator of
EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.

Authors
Jean L. Grem, Mary G. Quinn, Bruce Keith, Brian P. Monahan, J. Michael Hamilton, Yan Xu, Nancy Harold,
Dat Nguyen, Chris H. Takimoto, Anthony Rowedder, Janet Pang, Geraldine Morrison, and Alice Chen

This article is available at EngagedScholarship@CSU: https://engagedscholarship.csuohio.edu/scichem_facpub/167

487

488

intracellular metabolism to 5¢-ﬂuorodeoxyuridine
monophosphate (FdUMP). In the presence of 5,10methylenetetrahydrofolate, FdUMP forms a covalent
complex with thymidylate synthase (TS), resulting in
depletion of thymidine triphosphate (dTTP) and
interference with DNA synthesis and repair [2]. Leucovorin (LV) is used to increase the reduced folate
pools and increase the stability of the ternary complex.
The ribo- and deoxyribonucleotide triphosphate
derivatives of 5-FU are incorporated into RNA and
DNA, respectively, interfering with their function.
However, ﬂuorouridine triphosphate formation in vitro does not generally occur with FUDR exposure,
thus providing more selective inhibition of TS.
There is evidence supporting the combined use of
deoxycytidine analogs such as gemcitabine and ﬂuoropyrimidines. In clonogenic studies, exposure to
cytarabine, which shares the same metabolic pathways
as gemcitabine, for 24 h prior to the 5-FU resulted in
cytotoxicity that was at least additive, while the reverse
sequence resulted in marked antagonism [3]. The DNA
synthetic inhibition imposed by 5-FU signiﬁcantly
decreased cytarabine incorporation into DNA, thus
accounting for the sequence-dependant antagonism. In
HT-29 human colon cancer cells, sequential exposure
to gemcitabine (4 h) followed by FUDR (24 h) resulted in more than additive cytotoxicity and enhanced
DNA fragmentation [4]. Further, some patients with
pancreatic cancer refractory to 5-FU may still beneﬁt
from gemcitabine, suggesting lack of cross resistance
[5].
In preclinical studies, the concentration of gemcitabine required for the same degree of growth inhibition is
considerably less with prolonged exposure [6]. In vivo
models also suggest that prolonged gemcitabine infusions provide better results than bolus injections [7].
Since the plasma half-life of gemcitabine in patients is
brief and the formation of dFdCMP is saturable [8, 9],
continuous infusion oﬀers theoretical advantages over
the typical 30-min infusion. Clinical evidence indicates
that continuous infusion of 5-FU is associated with a
better toxicity proﬁle and better eﬃcacy than bolus
administration [10, 11, 12, 13].
We therefore conducted a phase l trial involving
gemcitabine, FUDR and LV. Initially, gemcitabine was
given as a 24-h infusion weekly for 3 of 4 weeks. The
starting dose of 150 mg/m2 was selected on the basis of
the recommended dose of 180 mg/m2 found in a prior
trial [14]. We planned to add FUDR as a 24-h infusion
starting after each gemcitabine dose cycle 2; low-dose
oral LV was given for 2 days starting 1 day prior to
FUDR on each treatment week. Since the toxicity was
unexpectedly severe, the duration of the gemcitabine
infusion was sequentially shorted to 2 h and then 1 h
with a starting dose of 1000 mg/m2. The clinical results,
achieved plasma concentrations of gemcitabine and
dFdU, and assessment of TS ternary complex formation
during gemcitabine and FUDR therapy are reported
here.

Patients and methods
Eligibility criteria
Patients 18 years of age or older with solid tumors who had failed
standard therapy for their disease or for whom no such therapy
was available were eligible for this trial provided their perfor
mance status was 0 2, the patient had recovered from prior
therapies, the absolute granulocyte and platelet counts were
>2000/ll and ‡100,000/ll, respectively, and the serum bilirubin
and creatinine were £ 2.0 mg/dl. Exclusion criteria included dis
ease progression on prior gemcitabine, pregnant or nursing wo
men, serious concurrent illness which would jeopardize the ability
to receive the protocol treatment, active infections, and primary
or secondary central nervous system malignancies. This study had
the approval of the local Institutional Review Boards and the
Cancer Therapy Evaluation Program, National Cancer Institute
(NCI). All patients gave written informed consent.

Treatment plan
Gemcitabine hydrochloride was supplied by the Cancer Therapy
Evaluation Program, Division of Cancer Treatment and Diagno
sis, NCI (Bethesda, Md.). Sterile FUDR was purchased from
Roche Laboratories (Nutley, N.J.). Therapy was administered in
the outpatient setting. Prophylactic antiemetics or other classes of
premedication were not employed. To ensure its tolerability,
gemcitabine was given alone for the initial cycle weekly for 3 of
4 weeks at a starting dose of 150 mg/m2 over 24 h. Due to unto
ward clinical toxicity, the protocol was amended to change the
dose and duration of gemcitabine to 1000 mg/m2 given over either
2 h or 1 h. The cycle was to be terminated early and considered
complete for a platelet count <50,000/ll, a granulocyte count
<500/ll, grade 2 or worse nonhematologic toxicity (excluding
nausea/vomiting) prior to week 3 dosing. If all three doses were
given, the gemcitabine dose was to be decreased one dose level if
the patient had grade 2 or worse nonhematologic toxicity, grade 3
hematologic toxicity, or required a delay of 1 week to permit
resolution of toxicity. The gemcitabine dose was decreased two
dose levels if the patient could not receive all three planned doses,
or for those patients who experienced grade 3 or worse nonhe
matologic or grade 4 hematologic toxicity, and in those who
required a delay of 2 weeks or more for resolution of toxicity. If a
gemcitabine dose reduction was required, the patient received a
second cycle of gemcitabine alone. FUDR was subsequently given
following each gemcitabine dose at a starting dose of 5 mg/m2
over 24 h. Oral leucovorin 20 mg/m2 was given for 2 days starting
1 day prior to each dose of FUDR. The 24 h infusions of gem
citabine and FUDR were given through a central catheter using a
portable infusion pump, whereas the 1 or 2 h infusions could be
given through a peripheral vein if a central catheter was not yet
available.
The dose of FUDR was escalated in new patient cohorts
according to the degree of toxicity experienced at the prior dose
level. If grade 1 toxicity (excluding nausea and vomiting) attrib
utable to FUDR occurred in one or more patients, the FUDR dose
was increased 2 fold. If grade 1 toxicity attributable to FUDR
occurred in two patients or grade 2 toxicity occurred in one patient,
the FUDR dose was increased 1.5 fold. If dose limiting toxicity
occurred in one patient, two to ﬁve additional patients were to be
entered at the same level. If dose limiting toxicity occurred in two
patients, then this dose level was considered to exceed the maxi
mum tolerated dose (MTD), and additional patients were entered
at the preceding dose level. The recommended dose was deﬁned as
one dose level below that associated with dose limiting toxicity in
two patients. Individual patients were allowed to escalate to the
next dose of FUDR provided that nonhematologic toxicity was no
more than grade 1 in severity and hematologic toxicity was no
more than grade 2 in severity for the preceding two cycles. The
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FUDR dose was reduced if the patient experienced dose limiting
toxicity or required a treatment interruption as described above for
gemcitabine.
The treatment was resumed on day 28 if the absolute granu
locyte count was ‡1500/ll, the platelet count was ‡75,000/ll and all
clinically signiﬁcant nonhematologic toxicities had resolved. The
dose of either gemcitabine or FUDR was altered based on the most
severe toxicity. If clinical toxicity recurred during the subsequent
cycle despite the prior dose reduction, the dose of the other drug
was then decreased.

Patient evaluation and follow up
A history and physical examination, performance status assessment,
complete blood count (CBC) and white blood cell (WBC) diﬀer
ential, blood urea nitrogen, creatinine, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline phosphatase,
bilirubin, albumin, tumor markers and urinalysis were performed at
the start of each cycle. CBC and WBC diﬀerential were done twice
weekly. Radiographic scans needed for disease measurement per
disease site were done pretreatment and every three cycles. Therapy
was continued until there was evidence of disease progression as
long as the patient agreed and the treatment was tolerated. A
complete remission was deﬁned as complete disappearance of all
evidence of tumor and return of abnormal blood tests to normal
levels for a minimum of 4 weeks. A partial response was a decrease
by at least 50% in the sum of the products of the perpendicular
diameters of all measured lesions in the absence of progression of
any lesion or the appearance of any new lesions for at least 4 weeks.
Stable disease was a change in measurable disease too small to meet
the requirements for partial response or progression, provided there
was no worsening of symptoms. Development of a new site of
malignant disease or an increase (>25%) in either the baseline
measurements or those obtained at best response constituted disease
progression. Toxicity was assessed using version 1 of the NCI
Common Toxicity Criteria.

Pharmacokinetic studies
Blood was collected in 10 ml draw heparinized tubes to which
10 nmol tetrahydrouridine (Sigma, St. Louis, Mo.) had been
added. The tubes were placed on ice immediately and centrifuged
for 10 min at 800 g; and the plasma was removed and stored at
)70C. Blood samples were taken during the infusions at the
following time points: 24 h infusion, 22 and 23 h; 2 h infusion, 90
and 105 min; 1 h infusion, 30, 40 and 50 min.
dFdU was provided by Lilly Research Laboratories (India
napolis, Ind.) through a material transfer agreement with the
National Cancer Institute. The internal standard, 5¢ deoxy 5
ﬂuorouridine (5¢ DFUR), was obtained from Sigma (St. Louis,
Mo.). Ammonium acetate was from Aldrich (Milwaukee, Wis.).
HPLC grade water and methanol were from Fisher (Fair Lawn,
N.J.). Tetrahydrouridine (lot no. 112907 J/22) was provided by the
Drug Synthesis and Chemistry Branch at the National Cancer
Institute (Bethesda, Md.). Pooled donor plasma was provided by
the Department of Transfusion Medicine, Warren G. Magnusen
Clinical Center, National Institutes of Health (Bethesda).
The plasma concentrations of gemcitabine and dFdU for the
1 h and 2 h infusions were analyzed using our validated reversed
phase HPLC method with photodiode array detection as previ
ously described [15]. Since the plasma levels for the 24 h infusion
of gemcitabine were anticipated to be below the limit of detection
for the HPLC assay, we developed a validated, liquid chroma
tography method with mass selective detection [16]. After the
addition of 250 ng 5¢ DFUR, a 0.5 ml plasma sample was diluted
with an equal volume of phosphate buﬀered saline (PBS, 1·,
pH 7.4). Solid phase extraction was performed using an Oasis
HLB 3 ml cartridge (Waters, Milford, Mass.) that had been
conditioned with 3 ml methanol and 3 ml PBS. After loading the

sample, the cartridge was washed with 2 ml PBS, and the analytes
were eluted with 2 ml methanol. The eluate was evaporated to
dryness and reconstituted in 0.5 ml HPLC grade water. After
vortex mixing, the solution was ﬁltered through a GHP Acrodisc
syringe ﬁlter (Pall Corporation, Ann Arbor, Mich.), then trans
ferred to an autosampler vial. Separation was achieved with a
YMC ODS AQ (5 lm, 120 Å, 2.0 · 150 mm) column, obtained
from Waters, preceded by a SecurityGuard C18 guard column
(Phenomenex, Torrance, Calif.). A Waters 2960 separations
module was set at 4 C; the column temperature was 30 C.
The initial composition of the mobile phase was 2% methanol/
98% 5 mM ammonium acetate at pH 6.8 (v/v). An isocratic
gradient was used at 0.2 ml/min for 3 min, followed by a linear
gradient over 4 min to 30% methanol/70% 5 mM ammonium
acetate, pH 6.8. The gradient was returned to initial conditions
over 2 min and remained there for 6 min. The retention times of
dFdC, dFdU and 5¢ DFUR were 11.5, 12.6 and 13.6 min. A
Micromass Platform LC MS detector (from Waters) was operated
in negative electrospray ionization mode. Single ion monitoring
(SIM) mode was used for analyte quantitation at m/z 262 for
[dFdC H]), m/z 263 for [dFdU H]), and m/z 245 for [5¢ DFUR
H]). The average recoveries for dFdC, dFdU, and 5¢ DFUR were
88.4%, 84.6%, and 99.3%, respectively. The linear calibration
ranges were 5 1000 ng/ml for dFdC, and 5 5000 ng/ml for dFdU.
The intra and interassay precisions (%CV) were £ 3% and
£ 7% at three concentration levels (50, 500, and 5000 ng/ml). The
limits of quantitation deﬁned as ten times signal to noise ratios
were 3.16 ng/ml for dFdC and 1.35 ng/ml for dFdU.
The area under the curve was determined by noncompartmental
methods using a continuous intravenous infusion model with
WinNonLin 4.0 (Pharsight Corporation, Mountain View, Calif.).
The graphs were prepared using SigmaPlot 8.02 for Windows
(SPSS, Chicago, Ill.).

Assessment of thymidylate synthase inhibition
In patients who had not received prior pelvic radiation and were
not receiving therapeutic anticoagulation, paired bone marrow
aspirates were planned immediately prior to therapy and again at
the end of the initial 24 h FUDR infusion. The samples were ﬁrst
passed through a 400 lm 25 mm ﬁlter disc held in a Swinnex
(Millipore) ﬁlter holder to remove bone spicules and fat globules.
The mononuclear cells were isolated by Ficoll Hypaque density
centrifugation; erythrocytes were removed with a brief hypotonic
lysis step, and the intact cell pellet was stored at )80C. On the day
of analysis, a protease inhibitor cocktail was added to the pellets,
the cell membranes were disrupted by sonication, and the lysate
was isolated after centrifugation at 12,000 g for 15 min at 4 C.
Equal amounts of protein (50 lg) were resolved by 10% sodium
dodecyl sulfate polyacrylamide gel electrophoresis as previously
described [17].

Results
Patients
Entered into this trial were 42 adult patients (Table 1);
93% had no more than minor cancer-related symptoms.
The majority had colorectal or pancreatic cancer, and
patients had received a median of two prior chemotherapy regimens. Nine patients with no prior chemotherapy were added to the then current dose level to
avoid delays in initiating therapy. Eight patients received
a median of two cycles with a 24-h infusion of gemcitabine (range one to nine). Seven patients received a 2-h
gemcitabine infusion; the median number of cycles was
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Table 1 Patient characteristics
Age (years)
Median
Range

51
23 77

Male/female

22/20

Performance status
0
1
2

15
24
3

No. of patients with prior therapy
Chemotherapy
Immunotherapy
Radiotherapy

32
9
6

No. of prior chemotherapy regimens
Median
Range

2
0 5

Origin of primary tumor
Colorectal
Pancreas
Lung
Appendix or small intestine
Unknown primary
Other

13
10
6
3
3
7

three (range one to six). Among 27 patients who received
a 1-h gemcitabine infusion, a median of four cycles was
given (range 1–21).
Clinical toxicity during the initial cycle with
gemcitabine alone
Due to concern about interpatient diﬀerences in sensitivity to gemcitabine and the potential for additive toxicity with the addition of FUDR, gemcitabine was given
alone in cycle 1, and a conservative dose-modiﬁcation
scheme was adopted for gemcitabine. Table 2 presents
the hematologic toxicities occurring during cycle 1
according to the dose and duration of gemcitabine
infusion. With a 24-h infusion, none of three patients
who received 150 mg/m2 could tolerate more than two
weekly doses due to grade 2 mucositis and grade 3
fatigue (one patient) or grade 3 thrombocytopenia (two
patients). In the interest of patient safety, the starting
dose was decreased to 100 mg/m2 for the next ﬁve
patients. One patient withdrew from the study after
receiving a single dose; she experienced grade 1 nausea

and lightheadedness, but felt that further side eﬀects
were unacceptable. Therapy was interrupted in another
patient after one dose due to small-bowel obstruction
requiring surgical bypass. One patient experienced
grade 4 neutropenia after two doses of gemcitabine, but
tolerated the subsequent cycle at a reduced dose of
60 mg/m2. Two patients who experienced grade 3 neutropenia after receiving all three weekly doses received a
dose reduction to 80 mg/m2 for the second cycle.
Based on this experience, the toxicity associated
with the 24-h infusion was deemed to be excessive. The
protocol was amended to utilize a 2-h infusion of
1000 mg/m2. Seven patients were enrolled. Four patients
received only two doses of gemcitabine. In one, this was
due to the onset of disease-related jaundice. Two of the
four patients experienced grade 3 thrombocytopenia,
and the dose of gemcitabine was decreased to 600 mg/m2
for the second cycle, and the other patient had grade 2
fatigue, fever and headache, but tolerated 800 mg/m2 the
next cycle. Among three patients who got all three
weekly doses, two required a dose reduction in the second cycle to 800 mg/m2 for grade 3 neutropenia and
thrombocytopenia (one patient each).
Since only one patient tolerated the initial cycle with
1000 mg/m2 over 2 h, the infusion duration was shortened to 1 h. Of 27 patients, 2 had the cycle interrupted
after a single dose of gemcitabine to allow either palliative radiation therapy to a preexisting left femoral
metastasis, or biliary stenting for disease-related
obstruction. In the second cycle, both tolerated all three
doses without appreciable toxicity. Seven patients
required termination of cycle 1 after two doses due to
toxicity: grade 3 or 4 thrombocytopenia (two each),
grade 4 neutropenia (two patients, one of whom also
had grade 3 platelet toxicity and fatigue), and grade 2
diarrhea (one patient). Of 24 patients who received a
second cycle of therapy, 11 received a gemcitabine dose
reduction to either 800 (n=5) or 600 mg/m2 (n=6).
Clinical toxicity with the addition of FUDR
Since initiation of FUDR was delayed until a tolerable
dose of gemcitabine had been deﬁned for each patient,
a given dose level of FUDR might be administered
with diﬀerent gemcitabine doses. Additional patients

Table 2 Hematological toxicity cycle 1 with gemcitabine alone
Infusion
Dose
No. of patients
WBC nadir
duration (h) (mg/m2)
(·1000/ll)
Total Receiving all three
planned doses
Median
(range)

ANC nadir
(/ll)
Median
(range)

Platelet nadir Hemoglobin (g/dl)
(·1000/ll)
Nadir
Median
Median
Decrease from
(range)
(range)
baseline

24

2205 (946 2436)
696 (448 4897)
1323 (706 2134)
1166 (224 5054)

24 (16 26)
85 (66 284)
50 (33 147)
108 (16 272)

2
1

150
100
1000
1000

3
5
7
25a

0
2
3
19

3.5
1.6
2.3
2.4

(2.2
(1.2
(1.2
(0.5

4.0)
6.6)
3.7)
7.2)

8.4 (7.0 9.0)
10.1 (8 11.2)
8.9 (6.9 11.3)
10 (7.6 11.4)

)3.6
)2.5
)2.5
)2.1

()3.9
()4.2
()5.4
()5.6

to
to
to
to

)0.9)
)0.7)
)1.3)
1.4)

a
Two patients not included since therapy was interrupted after a single dose to permit palliative radiation therapy and biliary stent
placement, rather than for treatment related toxicity
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Table 3 Dose escalation of FUDR (the data are presented
according to dose rather than chronological order of patients)
Gemcitabine
Infusion
time (h)

Dose
(mg/m2)

24

100
80
60
80
1000
800
600
1000
1000
800
1000
1000
800
600
400

2
1

Patients

FUDR
(mg/m2)

Dose limiting toxicity
ﬁrst cycle with FUDR?

1
1
1
1
1
2
1
3
2
1
5
2
3
2
1

5
5
5
10
10
10
10
10
12.5
12.5
15.6
19.5
19.5
19.5
19.5

0
0
0
0
0
0
1 (grade 3 platelets)
0
0
0
0
0
0
0
1 (grade 3 platelets)

Table 4 Toxicity during the initial cycle with FUDR and gemcit
abine in 26 patients with paired cycles (one patient who received
only one weekly dose of gemcitabine/FUDR due to new onset of
obstructive jaundice is not included). Values are means±SD
Gemcitabine Gemcitabine P value
alone
plus FUDR (paired t test)
White blood cells (/ll)
Hemoglobin (g/dl)
Platelet (1000/ll)
Neutrophils (/ll)

3385±1181
9.76±1.06
130±45
1896±951

3373±1050
9.35±1.01
122±61
1849±749

0.964
0.036
0.409
0.821

Table 5 Numbers of patients with toxicity during the initial cycle
with FUDR and gemcitabine
Toxicity

Grade

Gemcitabine
alone

Gemcitabine
plus FUDR

Mucositis

1
2
1
2
3
1
1
2

0
0
15
0
0
2
19
3

3
1
7
2
1
3
14
1

Nausea/vomiting
Diarrhea
Fatigue

were added to a given FUDR dose level if suﬃcient
safety information did not permit escalation to the next
dose level. As shown in Table 3, 27 patients received
one or more cycles of gemcitabine with FUDR; four
entry dose levels ranging from 5 to 19.5 mg/m2 over
24 h were explored. Dose-limiting thrombocytopenia
was observed in one patient each at 10 mg/m2 and
19.5 mg/m2. The clinical toxicities during 26 matched
cycles in which patients received the same dose of
gemcitabine alone or with FUDR are compared in
Tables 4 and 5. With the exception of anemia, there
was no signiﬁcant diﬀerence between the nadirs in the

cycle without and with FUDR. Four patients (15.4%)
experienced grade 1 or 2 mucositis with the addition of
FUDR (one at 10, two at 15.6, and one at 19.5 mg/m2);
none had mucositis during the preceding cycle with
gemcitabine alone. Patients were allowed to escalate to
the next dose level of FUDR if they had minimal toxicity
the preceding two cycles, and the dose was decreased if
needed. A total of 111 cycles with gemcitabine and
FUDR were given.
When the worst grade of hematologic toxicity per
patient per dose level was considered, no instances of
grade 4 leukopenia, neutropenia or thrombocytopenia
occurred. Grade 3 thrombocytopenia was observed as
follows (mg/m2): 5, one of six patients; 10, two of nine
patients; 12.5, one of four patients; 15.6, none of eight
patients; and 19.5, four of ten patients. Two patients who
initially received 19.5 mg/m2 escalated to 24.5 mg/m2,
and one of these had grade 3 thrombocytopenia
during his third cycle at the higher dose. Prior to deﬁning the MTD of FUDR, the pharmaceutical supplier
provided notice of an impending shortage of the clinical
formulation of FUDR; therefore, the trial was closed
early.
Overall clinical toxicity in patients receiving 1-h
gemcitabine alone or with FUDR
The worst toxicities experienced by each patient across
all cycles of therapy in patients receiving gemcitabine
over 1 h are shown in Table 6. Hematologic toxicity
predominated, with grade 3/4 toxicities as follows: leukopenia 18.5%, anemia 26%, thrombocytopenia 30%,
and neutropenia 63%. Two patients had Clostridium
diﬃcile-associated diarrhea of grade 3 severity, but both
tolerated subsequent cycles at the same doses without
problems. After completion of the FUDR infusion
week 1 of cycle 5, a 72-year-old male with renal cell
cancer received two units of packed red blood cells for
symptomatic anemia (hemoglobin 8.5 g/dl). Later that
evening he was admitted to his local hospital’s intensive
care unit for acute onset of shortness of breath requiring
temporary intubation and aggressive diuresis; the serum
creatinine was elevated at 2.2 mg/dl. He recovered
within a few days. Subsequent cardiac evaluation with
an echocardiogram and a persantine/thallium scan were
unremarkable. This episode of noncardiogenic pulmonary edema was considered possibly related to therapy,
although transfusion-related acute lung injury may
represent a plausible alternative. A 45-year-old male
with adenocarcinoma of the appendix presented with
hypertension when he returned for cycle 9. Work-up
revealed hemolytic uremic syndrome on the basis of
elevated creatinine, thrombocytopenia, microangiopathic hemolytic anemia, and pathognomonic ﬁndings
on renal biopsy. He received intensive plasmapheresis
and antihypertensive therapy, with stabilization of his
renal function. No further protocol therapy was given to
either patient.
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Table 6 Worst toxicity per patient receiving gemcitabine by 1 h
infusion across all cycles of therapy (presented as the numbers of
patients with a given toxicity among a total of 27 patients)
Toxicity

Grade 1

Grade 2

Grade 3

Grade 4

Leukopenia
Anemia
Thrombocytopenia
Neutropenia
Nausea/vomiting
Mucositis
Diarrhea
Fatigue
Skin
Fever
Anorexia
Myalgias
Headache
Alopecia
Pulmonary
Hemolytic uremia

3
7
12
3
13
5
7
17
13
4
12
8
9
8
4
0

18
13
7
6
7
1
1
7
2
14
0
1
0
1
2
0

4
6
6
13
1
0
2a
2
0
0
0
0
0
0
0
0

1
1
2
4
0
0
0
0
0
0
0
0
0

a

1
1

Clostridium diﬃcile associated

Fig. 1 Gemcitabine (dFdC) and 2¢,2¢ diﬂuorodeoxyuridine (dFdU)
plasma levels during the initial infusion. The data for each time
point are shown as the means±SD

Clinical outcome
Measurable disease was not required for the study.
Three patients were not assessable for response (withdrew from study after one cycle, two patients; evaluable
but nonmeasurable disease, one patient). Of 39 patients
assessable for response, 3 partial responses were seen
(one patient with heavily pretreated breast cancer, and
two previously untreated patients with adenocarcinoma
of unknown primary and pancreatic cancer). All three
received a 1-h gemcitabine infusion, and they remained
on study for 262, 666, and 813 days, respectively. Of the
remaining 36 patients assessable for response, 14 had
stable disease lasting 3 months or longer, and 22 experienced disease progression within 3 months.
Gemcitabine pharmacokinetics
Pharmacokinetic sampling was performed in 55 cycles in
39 patients with adequate venous access. Figure 1 shows
the plasma concentration (Cp) of gemcitabine and dFdU
during the initial infusion of 1000 mg/m2 gemcitabine
according to duration of infusion. With the 2-h infusion,
no diﬀerence was seen in the Cp between the 90-min and
105-min samples, indicating that steady-state had been
achieved. With the 1-h infusion, there was a trend for the
Cp at 50 min to be higher than the 30-min value
(P=0.08), whereas there was no signiﬁcant diﬀerence
between the 40-min and 50-min values. For both infusion durations, the Cp of dFdU increased throughout
the infusion. The AUClast (mean±SD) for gemcitabine
for the 1-h (n=23) and 2-h (n=7) infusions were
947±283 and 988±209 nmol/mlÆmin, and for dFdU
were 2670±682 and 4704±1532 nmol/mlÆmin. Figure 2
shows the maximum concentration (Cmax) values as a
function of gemcitabine dose rate (total milligrams per
minute). There was a strong correlation between dose
rate and Cmax for both gemcitabine and dFdU. If only

the data for the 1-h and 2-h infusions are considered
(Fig. 2, inset), the correlation for gemcitabine was
moderately strong (r=0.582, P=3.45·10 8), and there
was no correlation for dFdU (r=0.23). The results were
similar when dose rate expressed as milligrams per
minute per meter squared was used (data not shown).
Plasma samples were obtained during weeks 1 and 3
in 31 cycles. There was no diﬀerence in the average Cp
after either dose (1-h and 2-h combined): 23.81 lM
versus 25.22 lM (P=0.18, paired t-test). The average
Cp during the cycle (Table 7) for the 1-h infusion was
1.84-fold higher than that measured for the 2-h infusion,
and the ratio of dFdU to gemcitabine was about threeand ﬁvefold, respectively. For the 1-h and 2-h infusions,
there was no appreciable diﬀerence in the AUClast based
on gender (median, 25th percentile, 75th percentile) for
either gemcitabine [female, 1052 nmol/mlÆmin (888–
1228 nmol/mlÆmin); male, 947 nmol/mlÆmin (840–
1028 nmol/mlÆmin; P=0.220, rank sum test)] or dFdU
[female, 3147 nmol/mlÆmin (2958–3899 nmol/mlÆmin);
male, 2958 nmol/mlÆmin (2358–3230 nmol/mlÆmin)].
With the 24-h infusion, the Cp for gemcitabine averaged 61 nM and 50 nM for 150 and 100 mg/m2, and the
ratio of dFdU to gemcitabine was much greater than
observed with the shorter infusions. Following the initial
infusion of 150 mg/m2 (n=3) and 100 mg/m2 (n=4)
gemcitabine, the AUClast (mean±SD) for gemcitabine
were 46±11 and 39±22 nmol/mlÆmin, and for dFdU,
the corresponding values were 7650±1513 and
3468±1260 nmol/mlÆmin. Clearance during the initial
cycle was calculated by dividing the dose rate by the
steady-state Cp (24-h and 2-h infusion); the median
values were 5961 ml/min/m2 (25%/75% percentiles,
3988/8703 ml/min/m2) and 2107 ml/min/m2 (25%/75%
percentiles, 1722/2259 ml/min/m2), respectively. Clearance for the 1-h infusion was estimated by dividing the
dose rate by the average of the 40-min and 50-min
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Fig. 2 The maximum plasma
concentrations (Cmax) of dFdC
and dFdU achieved are plotted
against the gemcitabine dose
rate. The data are from 93
gemcitabine infusions given
over 24 h (n=16), 2 h (n=18)
or 1 h (n=57). The Pearson
correlation coeﬃcients are
shown. Inset data for
gemcitabine Cmax in patients
receiving a 2 h or 1 h infusion

Table 7 Average gemcitabine and 2’,2’ diﬂuorodeoxyuridine (dFdU) plasma concentrations. The average plasma concentrations at the
various time points were calculated for each patient. If a patient had blood sampling during two infusions of a cycle, the results were
averaged. Values are means±SD
Gemcitabine

Number of patients
2

Infusion duration (h)

Dose (mg/m )

1

1000
800
600
400
1000
800
600
150
100
80
60

2
24

a

23
4
4
1
7
3
2
3
5
2
1

Plasma concentration (lM)
Gemcitabine

dFdU

30.38±7.96
24.76±8.37
18.75±7.65
23.8
16.32±3.36
10.72±1.53
11.38±1.22a
0.061±0.012
0.0496±0.0231
0.0397±0.008a
0.0211

86.75±22.39
75.20±13.25
49.16±6.30
57.15
81.41±24.61
94.09±9.02
67.95±5.45a
11.17±2.50
6.31±1.66
7.57±0.33a
3.01

Ratio dFdU to dFdC

3.0±0.9
3.2±0.7
3.1±0.8
2.4
5.1±1.5
9.0±1.7
6.0±0.1
188±18
166±86
300±72a
121

Range ·0.5

samples: the median was 2076 ml/min/m2 (25%/75%
percentiles, 1833/2265 ml/min/m2).
Patients with mild renal dysfunction (serum creatinine <2.0 mg/dl) were eligible for this protocol. The
median baseline serum creatinine for all patients was
0.9 mg/dl (range 0.5–1.8 mg/dl); only two patients had
serum creatinine values above the upper limit of normal
(1.3 mg/dl). To assess any potential eﬀect of renal
function on the pharmacokinetics of gemcitabine and
dFdU, the creatinine clearance for cycle 1 was estimated
using the Cockcroft-Gault formula. The median value

was 93 ml/min (range 32–179 ml/min). Because the
gemcitabine and dFdU AUClast for the 24-h infusion
were signiﬁcantly diﬀerent from the values for the 1-h
and 2-h infusions, the analysis was restricted to the two
shorter infusions. If the data were analyzed by separating the values into two groups, i.e. the lowest third
( £ 75 ml/min, n=10) versus the upper two-thirds
(‡76 ml/min, n=20), however, the dFdU AUClast appeared to be higher in those patients with lower estimated
creatinine clearance values: median (25th/75th percentiles): 3421 nmol/mlÆmin (3053/4465 nmol/mlÆmin)
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Thymidylate synthase ternary complex
formation during FUDR

Fig. 3 Assessment of bound and free thymidylate synthase in
paired bone marrow mononuclear cell samples obtained pre and
during the FUDR infusion. The ‘‘pre’’ sample was obtained prior
to receiving any protocol therapy; the ‘‘post’’ sample was taken at
the end of the 24 h FUDR infusion

Paired bone marrow aspirates were obtained from 21
patients prior to cycle 1 therapy and toward the end of
the initial FUDR 24-h infusion. A representative
immunoblot is shown in Fig. 3. In the pretherapy samples, a single band at )35 kDa representing unbound TS
was seen. In the samples obtained during FUDR infusion, a slower migrating band at )37 kDa was evident
that represents bound TS. The extent of ternary complex
formation was not clearly diﬀerent over the 3.9-fold dose
range of FUDR (Fig. 4).

Discussion

Fig. 4 Thymidylate synthase ternary complex formation in bone
marrow mononuclear cells obtained at the end of the 24 h FUDR
infusion. The number of patients is shown in parentheses. The data
are shown as the mean±SD (or 1/2 range if n=2)

vs 2611 nmol/mlÆmin (21453191 nmol/mlÆmin; P=0.019,
rank sum test). This is consistent with the diﬀerences in
the mode of elimination between gemcitabine (metabolic) and dFdU (renal).
Possible pharmacodynamic relationships were
explored for 35 patient-cycles for gemcitabine given as
a 1-h infusion (24 cycle 1, 11 cycle 2). The median
dose was 1000 mg/m2 (range 600–1000 mg/m2). There
was no relationship between gemcitabine dose in milligrams (maximum/minimum dose=2.8) and either the
average gemcitabine Cp or the degree of hematologic
toxicity (data not shown). For these cycles, the median
Cp was 29.4 lM (range 9.5–44.2 lM). The average
gemcitabine Cp did not correlate with the degree of
hematologic toxicity (data not shown), suggesting that
either the range of Cp was not great enough to permit
pharmacodynamic correlates, or that other host
factors play a greater role in determining hematologic
toxicity.

With the current trial design, gemcitabine was given
alone to establish a tolerable dose in each patient before the introduction of FUDR. A conservative dose
modiﬁcation scheme was used, such that the dose of
gemcitabine was decreased for grade 3 and grade 2
hematologic and nonhematologic toxicity, respectively,
or if all three weekly doses could not be given due to
treatment-related toxicity. Although this strategy meant
that diﬀerent FUDR dose levels would be given with
diﬀerent gemcitabine doses, we felt that this design was
in the best interests of patient safety. Further, the
toxicity in the cycle in which FUDR was added could
be compared to the prior cycle in which toxicity had
been tolerable.
Gemcitabine displays exceptional schedule-dependent
toxicity when given as a single agent. With a 6-h weekly
infusion of gemcitabine for 3 of 4 weeks, the recommended dose is 250 mg/m2 (0.694 mg/m2 per min) [18].
Based on pharmacokinetic and cell cycle considerations
along with preclinical data indicating that longer exposures to gemcitabine are more cytotoxic, a 24-h infusion
has been explored in several trials, including the current
one. Previously trials have led to recommended gemcitabine doses of either 100 or 150 mg/m2 [14, 19]. In the
present study, we found that gemcitabine doses of 100 to
150 mg/m2 over 24 h (0.069 and 0.104 mg/m2 per min)
were poorly tolerated. This is the ﬁrst report of the
plasma concentrations of gemcitabine and dFdU
achieved with a 24-h infusion schedule, accomplished
through the development of a novel LC-MS assay. With
100 and 150 mg/m2, the gemcitabine steady-state Cp
levels were in the 50–60 nM range. An apparent threefold increase in clearance was observed with the 24-h
infusion. These results conﬁrm that the MTD of gemcitabine decreases appreciably as the duration of infusion increases. We did not incorporate cellular
pharmacology studies of gemcitabine, but assessment of
dFdCTP formation might have proven informative.
Development of nonradioisotopic methods to measure
gemcitabine-DNA incorporation would surely provide
an important investigative tool.
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Both the activation and deactivation of gemcitabine
are saturable. Pharmacodynamic studies in patients
indicate that the formation of dFdCTP in mononuclear
cells reaches a plateau at 20 lM, and a dose-rate of
10 mg/m2 per min has been proposed to avoid saturation of deoxycytidine kinase [8, 9, 20]. Following several
dose-ﬁnding trials using this infusion rate, a total dose of
1500 mg/m2 has been recommended [21, 22, 23]. In one
phase I trial in which 27 patients were treated with 1200,
1500 or 1800 mg/m2 gemcitabine given over 2–3 h,
incidences of grade 3/4 neutropenia and thrombocytopenia of 58% and 27%, respectively, were found [21]. In
another trial, grade 4 neutropenia and grade 3/4
thrombocytopenia each occurred during the initial cycle
at 1500 mg/m2 over 150 min in 37.5% of patients. When
all cycles at this dose were considered, 27% and 58%
of cycles were complicated by these degrees of toxicity, respectively [22]. Mani et al. reported grade 3/4
neutropenia in 40% of patients receiving 10 mg/m2
per min for 150 min [23]. In our trial, only three of six
assessable patients received all three planned gemcitabine doses during the initial cycle of 1000 mg/m2 over
2 h (8.3 mg/m2 per min), and two of these required dose
reductions for their second cycle. We therefore explored
a 1-h infusion of 100 mg/m2 gemcitabine (16.67 mg/m2
per min). Due to the small number of patients, and the
diﬀerences in dose modiﬁcation schemes, it is not possible to comment on whether our results with the 2-h
infusion are truly at odds with those reported in the
literature for the 10 mg/m2 per min infusion strategy.
With gemcitabine given as a 1-h infusion, 18 of 25
assessable patients (72%) treated with 1000 mg/m2 were
able to receive all three planned doses during their initial
cycle, but ﬁve of these received a dose reduction of
gemcitabine for cycle two.
We selected a continuous infusion of FUDR given
over 24 h based on our preclinical data. Although
FUDR is primarily used for regional therapy, there is
clinical experience with continuous intravenous infusion [24, 25, 26, 27]. The daily dose of FUDR given
for 14 of 28 days in the intravenous arm of several
randomized clinical trials comparing systemic with
hepatic arterial infusion was 5.6 mg/m2 (0.15 mg/kg)
[25, 26, 27]; diarrhea was dose-limiting. The addition
of low-dose leucovorin (5 mg/m2 per day) reduced the
recommended dose of FUDR by 50% [28]. FUDR
28–37 mg/m2 per day was recommended for a 5- to 7day continuous infusion; mucositis and diarrhea were
dose-limiting [29]. The addition of high-dose oral
leucovorin reduced the recommended dose of FUDR
to 11 mg/m2 per day for 5 days, and myelosuppression
became dose limiting [30]. Since there was no published experience with FUDR given as a weekly 24-h
infusion when this protocol was designed, a conservative starting dose of 5 mg/m2 was selected. In 26
matched cycles in which FUDR was added to the
same dose of gemcitabine, there was no evidence of
increased myelosuppression, diarrhea, nausea/vomiting, or fatigue, but there was a trend for a greater

incidence of mucositis. Although we were unable to
deﬁne the MTD of FUDR due to drug supply issues,
we documented ternary complex formation of the
target enzyme during the FUDR infusion despite the
low doses of FUDR and leucovorin that were used.
Measurement of TS catalytic activity is an alternative
to immunoblot techniques, but requires the use of a
radioisotope, and can be insensitive in detecting inhibition of the enzyme if the basal enzyme activity is
low.
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